Safe Harbor Statement
Certain statements contained in this presentation or in other Company documents and certain statements that may be made by management of the Company orally in presenting this material may contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by the fact that they do not relate strictly to historic or current facts. They use words such as "estimate," "expect," "intend," "believe," "plan," "anticipate" and other words and terms of similar meaning in connection with any discussion of future operating or financial performance or condition. In particular, these include statements concerning future actions, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings and financial results.
Because actual results are affected by risks and uncertainties, the Company cautions investors that actual results may differ materially from those expressed or implied in any forward-looking statement. It is not possible to predict or identify all such risks and uncertainties. The Company identifies some of those risks in its Securities and Exchange Commission filings on forms 10-K, 10-Q and 8-K , and investors are advised to consult the Company’s recent filings for a more complete listing. Factors that could cause the actual results to differ materially from expected and historical results include, but are not limited to: successful completion of the disposition of the Company's drug delivery technologies pursuant to the transactions described in this release, including the Company's obtaining of necessary approvals and consents to the transaction; the ability of the acquirer of the drug delivery technologies to develop and market products based on those technologies; the Company's continued ability to operate its clinical services business pending development and execution of a plan for disposing of that business; sales demand; the timing of customers' projects; continued plant operating efficiencies, including the resumption of normalized production at the Company’s new Kinston, NC facility; the outcome of litigation involving the January 2003 explosion and fire at its former Kinston NC facility, the Company's ability to maintain its market position and pricing in the face of lower-cost competitors, particularly in the European marketplace; the Company's ability to maintain a favorable mix of value-added products in its portfolio; continued strong contribution from the Company's affiliates; strength or weakness of the U.S. dollar; inflation; potential price increases in raw materials, including those that are petroleum-based, and the continued availability of raw materials; and the impact of recent tax legislation relating to repatriation of foreign earnings.
The Company assumes no obligation to update forward-looking statements as circumstances change. Investors are advised to consult any further disclosures that the Company makes or has made on related subjects in the Company's form 10-K, 10-Q and 8-K reports.
In presenting this material or responding to inquiries in connection with a presentation, management may refer to results or performance measures that are not prepared in accordance with US Generally Accepted Accounting Principles (“GAAP”) as reported in the Company’s recent 10Q and 8-K filings. These are Non-GAAP measures and are not intended to replace or as a substitute for results measured under GAAP, but rather as supplement to the GAAP reported results. Those 10-Q and 8-K filings include reconciliations of the GAAP and Non-GAAP results.